Mangoceuticals, Inc. Stock Price, News & Analysis

Mangoceuticals (NASDAQ: MGRX) announced an up to $100 million Solana-focused digital asset treasury (DAT) strategy on Dec 19, 2025 in partnership with Cube Group and a new subsidiary, Mango DAT, LLC.

The MULTI-DAT framework targets staking and DeFi yield with staked 7-8% APY and active management targeting 8-20% APY, and names Cube Group founders (Solana core developers) as asset manager. The company may use its shelf registration and ATM or other offerings to fund accumulation; no guarantee of full funding was stated.

Mangoceuticals (NASDAQ: MGRX) entered definitive agreements for a registered direct offering and a concurrent private placement expected to raise approximately $2.5 million. The transactions consist of the sale of 1,930,502 Common Units (or Pre-Funded Units), each including one share or one pre-funded warrant plus one PIPE Common Warrant to buy one share at an exercise price of $1.4245. The offering price per Common Unit is $1.295 (Pre-Funded Unit $1.29499). The offerings are priced at the market under Nasdaq rules and are expected to close on or about December 19, 2025, subject to customary conditions. Proceeds are intended for general corporate purposes and working capital. The registered offering relies on an effective Form S-3 declared effective June 24, 2025, and the company has agreed to registration rights for resale of issued securities.

Mangoceuticals (NASDAQ: MGRX) clarified that its newly launched MangoRx Direct and PeachesRx Direct weight-management programs are live as of November 14, 2025, offering telehealth consultations, personalized care plans, and ongoing support for $99 per month (medication cost separate).

Through a vetted third-party provider, the programs can facilitate valid prescriptions for FDA-approved branded GLP-1 medications, including Zepbound and Wegovy, and patients may fill prescriptions at any licensed pharmacy or manufacturer self-pay channels, subject to manufacturer supply availability. Mangoceuticals confirmed it has no direct contract with Eli Lilly or Novo Nordisk.

Mangoceuticals (NASDAQ: MGRX) launched MangoRx Direct and PeachesRx Direct on Nov 13, 2025 to provide telehealth access, clinical monitoring, and fulfillment for branded GLP-1 obesity drugs Zepbound (tirzepatide) via LillyDirect and Wegovy (semaglutide) via NovoCare. The company offers a medication-management membership at $99/month and states GLP-1 drugs are available at fixed cash-pay pricing starting $499/month with home delivery or local pharmacy pickup.

The release also notes a Novo Nordisk spokesperson saying Novo Nordisk has no agreement with Mangoceuticals, and references White House pricing initiatives targeting $245/month government prices and other program pricing changes in 2026.

Mangoceuticals (NASDAQ: MGRX) has announced breakthrough results for its patented antiviral compound MGX-0024 in poultry field studies. The compound, delivered through drinking water, achieved 100% survival against respiratory illnesses in large-scale trials conducted by Solice International. In a study of 10,000 chicks treated for 48 days, there were no deaths from respiratory diseases, compared to a 50% mortality rate in untreated control groups. MGX-0024, composed of natural polyphenols and zinc, is currently being evaluated for effectiveness against avian flu (H5N1). The company is scaling production and pursuing regulatory approvals in major markets including the US, UK, Canada, and Australia. MangoRx IP Holdings is also seeking a CAGE code to pursue US federal funding through USDA and BARDA programs.

Mangoceuticals (NASDAQ: MGRX) has announced the acquisition of Smokeless Technology Corp.'s intellectual property and related assets, marking its strategic entry into the oral pouch delivery market. The acquisition includes product formulations, know-how, distribution, and supplier relationships from the Canadian-based pouch innovation company.

The company plans to integrate Smokeless Tech's stimulant formulations with pharmaceutical ingredients under the MangoRx and PeachesRx brands. According to Skyquest, the U.S. nicotine pouch market reached $3.13 billion in 2024, with projections for the global oral pouch market to exceed $37.34 billion by 2032.

Additionally, MGRX has appointed Tim Corkum, former President of JUUL Labs Canada and Philip Morris International executive, to lead their pouch division. The company aims to leverage its existing distribution network, compounding pharmacy relationships, and planned Diabetinol launch to position itself as a nutraceutical platform with multi-format delivery potential.

Mangoceuticals Inc. (NASDAQ:MGRX) is expanding its presence in the health and wellness sector through innovative product offerings. The company's flagship product, Mango, offers ED treatment in two versions: Sildenafil Mango and Tadalafil Mango, featuring fast-acting dissolvable tablets with unique formulations.

The company's portfolio includes:

• Prime by MangoRx: A telehealth-enabled testosterone replacement therapy using Kyzatrex™, an FDA-approved oral testosterone capsule
• Grow by MangoRx: A comprehensive hair loss treatment combining Minoxidil, Finasteride, Biotin, and Vitamin D3
• Slim by MangoRx: An oral dissolving Semaglutide tablet for weight loss
• Diabetinol®: A patented plant-based nutraceutical for metabolic health

The company has also launched PeachesRx, a women's wellness brand, expanding their reach beyond men's health to create a comprehensive wellness ecosystem.

Mangoceuticals (NASDAQ: MGRX) has secured exclusive licensing and distribution rights for Diabetinol® in the United States and Canada, entering the $33.66 billion diabetes and metabolic health market. Diabetinol® is a patented plant-based nutraceutical derived from citrus peel, clinically proven to improve insulin sensitivity and metabolic function.

The product will be distributed in multiple formats including capsules, beverages, pouches, cookies, and gummies through direct-to-consumer channels, online retailers, brick-and-mortar stores, and affiliate marketing. The expansion targets the growing diabetes crisis, with over 30 million Americans suffering from type 2 diabetes and 97.6 million adults having prediabetes.

The company positions Diabetinol® as a more affordable alternative for individuals who cannot access or tolerate GLP-1 medications, addressing a significant market need as U.S. diabetes-related healthcare costs exceed $400 billion annually.

Mangoceuticals (NASDAQ: MGRX) has announced the launch of PeachesRx, a women's telehealth platform focusing on health and wellness products, initially specializing in GLP-1 receptor agonists for weight loss treatment. The platform will operate through www.PeachesRx.com, offering HIPAA-compliant telemedicine services.

The company is targeting the expanding GLP-1 market, where approximately 70% of weight loss prescriptions are written for women. The global GLP-1 market for weight management is projected to exceed $48 billion by 2030. The women's health market, valued at $49.33 billion in 2024, is expected to reach $68.53 billion by 2030, growing at a 5.1% CAGR.

Studies indicate that over 60% of telehealth users are female, positioning PeachesRx to capture this market segment. The company plans to expand beyond GLP-1 treatments into broader wellness categories, including sexual health, hair growth, and hormone therapy solutions.